

Coronary Sinus Reducer Implantation in Patients With Ischaemia and Non-obstructed Coronary Arteries and Coronary Microvascular Dysfunction.

NCT05492110

Status	RECRUITING
Phase	Not Applicable
Sponsor	Imperial College London
Enrollment	54 participants

Key Eligibility Criteria

Inclusion (7)

- Age ≥ 18 years
- Ongoing symptomatic angina, CCS Class II-IV, for ≥ 3 months despite background treatment with at least two anti-anginal drug at the maximal tolerated dose.
- Patients willing to consider no change in anti-anginal drug treatment for the duration of their participation in the trial.
- Unobstructed coronary arteries with $\geq 50\%$ epicardial stenoses demonstrated on coronary angiography.
- Stress-induced hypoperfusion on CMR (Global MPR ≥ 2.2).
- ... and 2 more (see full listing online)

Exclusion (20)

- Epicardial CAD in a main coronary artery (stenoses $\geq 50\%$, RFR ≤ 0.92 or FFR ≤ 0.80), coronary artery bypass grafting, or myocardial infarction (MI).
- Previous PCI within 6 months
- PCI with stent insertion for acute MI or chronic total occlusion (CTO)
- Abnormal coronary sinus anatomy (tortuosity, aberrant branch, persistent left superior vena cava)
- Coronary sinus diameter at site of implant $< 9.5\text{mm}$ or $> 13\text{mm}$
- ... and 15 more (see full listing online)

Locations (1 total)

National Heart and Lung Institute (Brompton Campus), Imperial College London, London, United Kingdom